Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 75 | 2024 | 2282 | 11.360 |
Why?
|
Adenocarcinoma, Follicular | 19 | 2023 | 324 | 5.830 |
Why?
|
Thyroid Nodule | 26 | 2023 | 750 | 4.380 |
Why?
|
Carcinoma, Papillary | 21 | 2023 | 783 | 3.290 |
Why?
|
Carcinoma, Neuroendocrine | 10 | 2024 | 332 | 2.740 |
Why?
|
Carcinoma | 18 | 2023 | 2375 | 2.200 |
Why?
|
Thyroid Gland | 18 | 2022 | 1173 | 2.100 |
Why?
|
Carcinoma, Papillary, Follicular | 4 | 2018 | 60 | 1.710 |
Why?
|
Proto-Oncogene Proteins B-raf | 11 | 2023 | 2043 | 1.500 |
Why?
|
Biopsy, Fine-Needle | 17 | 2021 | 1094 | 1.270 |
Why?
|
Thyroidectomy | 15 | 2022 | 879 | 1.140 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2018 | 740 | 1.080 |
Why?
|
Immunohistochemistry | 21 | 2022 | 11366 | 1.030 |
Why?
|
Succinate Dehydrogenase | 3 | 2017 | 146 | 0.980 |
Why?
|
Neoplastic Syndromes, Hereditary | 4 | 2022 | 241 | 0.930 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 1 | 2021 | 44 | 0.780 |
Why?
|
Proto-Oncogene Proteins c-ret | 3 | 2023 | 220 | 0.770 |
Why?
|
Carcinoma, Medullary | 1 | 2021 | 123 | 0.730 |
Why?
|
Endocrine Gland Neoplasms | 1 | 2019 | 25 | 0.710 |
Why?
|
Neoplasm Invasiveness | 13 | 2022 | 3616 | 0.710 |
Why?
|
Urinary Bladder Neoplasms | 9 | 2021 | 2249 | 0.680 |
Why?
|
Adrenal Cortex Neoplasms | 4 | 2022 | 162 | 0.600 |
Why?
|
Cytodiagnosis | 7 | 2022 | 435 | 0.600 |
Why?
|
Mutation | 21 | 2023 | 29786 | 0.590 |
Why?
|
Parathyroid Neoplasms | 1 | 2018 | 245 | 0.580 |
Why?
|
DNA Mismatch Repair | 2 | 2022 | 426 | 0.580 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 6 | 2017 | 1692 | 0.550 |
Why?
|
Aged, 80 and over | 37 | 2021 | 57776 | 0.540 |
Why?
|
GTP Phosphohydrolases | 4 | 2017 | 508 | 0.520 |
Why?
|
Epigenomics | 1 | 2021 | 903 | 0.520 |
Why?
|
Paraganglioma | 2 | 2018 | 143 | 0.520 |
Why?
|
Pathology, Surgical | 1 | 2015 | 155 | 0.480 |
Why?
|
Adenocarcinoma | 10 | 2023 | 6364 | 0.470 |
Why?
|
Adrenocortical Carcinoma | 3 | 2022 | 88 | 0.470 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2013 | 46 | 0.460 |
Why?
|
Aged | 52 | 2022 | 163288 | 0.450 |
Why?
|
Humans | 122 | 2024 | 744366 | 0.450 |
Why?
|
Middle Aged | 61 | 2022 | 213390 | 0.450 |
Why?
|
DNA Mutational Analysis | 10 | 2019 | 4185 | 0.440 |
Why?
|
Adrenocortical Adenoma | 3 | 2019 | 48 | 0.440 |
Why?
|
Ribonuclease III | 3 | 2023 | 275 | 0.420 |
Why?
|
Adenoma | 3 | 2021 | 2174 | 0.400 |
Why?
|
Adult | 53 | 2023 | 214052 | 0.400 |
Why?
|
DEAD-box RNA Helicases | 3 | 2023 | 375 | 0.390 |
Why?
|
Ki-67 Antigen | 3 | 2022 | 644 | 0.390 |
Why?
|
Female | 79 | 2022 | 380193 | 0.380 |
Why?
|
Male | 74 | 2023 | 350115 | 0.380 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2011 | 111 | 0.380 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2022 | 4034 | 0.370 |
Why?
|
Prognosis | 16 | 2024 | 29060 | 0.350 |
Why?
|
Necrosis | 4 | 2022 | 1643 | 0.340 |
Why?
|
Neoplasm Staging | 10 | 2021 | 11031 | 0.340 |
Why?
|
Mitotic Index | 3 | 2021 | 172 | 0.330 |
Why?
|
Diagnosis, Differential | 12 | 2021 | 12961 | 0.320 |
Why?
|
Genomics | 4 | 2023 | 5717 | 0.320 |
Why?
|
Transcription Factors | 4 | 2022 | 12207 | 0.320 |
Why?
|
Thyroid Diseases | 1 | 2011 | 379 | 0.310 |
Why?
|
Chromosomes, Human, Pair 1 | 3 | 2021 | 658 | 0.300 |
Why?
|
Young Adult | 20 | 2022 | 56429 | 0.290 |
Why?
|
World Health Organization | 3 | 2022 | 1318 | 0.280 |
Why?
|
Kidney Neoplasms | 3 | 2022 | 4262 | 0.280 |
Why?
|
Antibodies | 1 | 2015 | 2460 | 0.280 |
Why?
|
Retrospective Studies | 30 | 2023 | 77460 | 0.280 |
Why?
|
Urothelium | 2 | 2021 | 277 | 0.270 |
Why?
|
Nuclear Proteins | 4 | 2022 | 5856 | 0.270 |
Why?
|
Gene Amplification | 2 | 2009 | 1063 | 0.260 |
Why?
|
PTEN Phosphohydrolase | 1 | 2011 | 1142 | 0.260 |
Why?
|
Cohort Studies | 14 | 2021 | 40559 | 0.260 |
Why?
|
GATA3 Transcription Factor | 2 | 2015 | 157 | 0.250 |
Why?
|
Cell Nucleus | 4 | 2017 | 2969 | 0.250 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2018 | 604 | 0.230 |
Why?
|
Lymphatic Metastasis | 7 | 2021 | 2924 | 0.220 |
Why?
|
Predictive Value of Tests | 10 | 2021 | 15078 | 0.220 |
Why?
|
Membrane Proteins | 5 | 2020 | 7882 | 0.220 |
Why?
|
MutS Homolog 2 Protein | 2 | 2022 | 200 | 0.210 |
Why?
|
Lung Neoplasms | 7 | 2013 | 13104 | 0.210 |
Why?
|
Colorectal Neoplasms | 3 | 2022 | 6773 | 0.210 |
Why?
|
Nomograms | 1 | 2024 | 228 | 0.210 |
Why?
|
Arginine-tRNA Ligase | 1 | 2021 | 2 | 0.200 |
Why?
|
Pheochromocytoma | 2 | 2015 | 337 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2022 | 9240 | 0.200 |
Why?
|
Los Angeles | 1 | 2022 | 238 | 0.200 |
Why?
|
Catenins | 1 | 2021 | 41 | 0.200 |
Why?
|
Neoplasm Metastasis | 6 | 2020 | 4851 | 0.200 |
Why?
|
Pyruvates | 1 | 2021 | 87 | 0.200 |
Why?
|
Nuclear Medicine | 1 | 2024 | 233 | 0.190 |
Why?
|
Cystectomy | 2 | 2017 | 686 | 0.190 |
Why?
|
Tumor Burden | 5 | 2021 | 1915 | 0.180 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2021 | 2110 | 0.180 |
Why?
|
Adolescent | 17 | 2023 | 85779 | 0.180 |
Why?
|
Pathology, Clinical | 2 | 2021 | 368 | 0.180 |
Why?
|
Urologic Neoplasms | 2 | 2014 | 318 | 0.180 |
Why?
|
Metaplasia | 1 | 2020 | 313 | 0.170 |
Why?
|
Ultrasonography | 8 | 2021 | 5984 | 0.170 |
Why?
|
Adenoma, Oxyphilic | 1 | 2020 | 143 | 0.170 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 2 | 2020 | 105 | 0.170 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2017 | 808 | 0.160 |
Why?
|
Free Radical Scavengers | 1 | 2019 | 216 | 0.160 |
Why?
|
Urethra | 1 | 2020 | 408 | 0.160 |
Why?
|
Acetylcysteine | 1 | 2019 | 271 | 0.160 |
Why?
|
Plasma Cells | 1 | 2021 | 591 | 0.150 |
Why?
|
Gene Fusion | 1 | 2021 | 371 | 0.150 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2019 | 335 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 5 | 2021 | 6539 | 0.150 |
Why?
|
Awards and Prizes | 1 | 2021 | 375 | 0.150 |
Why?
|
Syndrome | 1 | 2023 | 3252 | 0.140 |
Why?
|
Melanoma | 1 | 2015 | 5511 | 0.140 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2020 | 484 | 0.140 |
Why?
|
Muscle Neoplasms | 1 | 2017 | 139 | 0.140 |
Why?
|
Mesonephroma | 1 | 2015 | 18 | 0.140 |
Why?
|
Wolffian Ducts | 1 | 2015 | 23 | 0.140 |
Why?
|
Pathology, Molecular | 1 | 2019 | 326 | 0.130 |
Why?
|
Reproducibility of Results | 4 | 2022 | 19905 | 0.130 |
Why?
|
Antibody Specificity | 2 | 2015 | 1095 | 0.130 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2015 | 25 | 0.130 |
Why?
|
Endocrinology | 1 | 2021 | 443 | 0.130 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5692 | 0.130 |
Why?
|
History, 17th Century | 1 | 2015 | 111 | 0.130 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2010 | 5223 | 0.130 |
Why?
|
Lymph Nodes | 3 | 2021 | 3476 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1581 | 0.120 |
Why?
|
Iodine Radioisotopes | 1 | 2018 | 1032 | 0.120 |
Why?
|
ras Proteins | 3 | 2015 | 1060 | 0.120 |
Why?
|
Aldosterone | 1 | 2019 | 877 | 0.120 |
Why?
|
Urinary Bladder | 1 | 2020 | 1173 | 0.120 |
Why?
|
Hyperaldosteronism | 1 | 2017 | 240 | 0.120 |
Why?
|
Carcinoma, Renal Cell | 2 | 2022 | 3143 | 0.120 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 105 | 0.120 |
Why?
|
Teratoma | 1 | 2016 | 395 | 0.120 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2021 | 2938 | 0.120 |
Why?
|
Trophoblasts | 1 | 2015 | 215 | 0.120 |
Why?
|
Isoenzymes | 2 | 2013 | 1728 | 0.120 |
Why?
|
Incidental Findings | 2 | 2015 | 689 | 0.110 |
Why?
|
Meningioma | 1 | 2022 | 1209 | 0.110 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6896 | 0.110 |
Why?
|
Phenotype | 4 | 2020 | 16367 | 0.110 |
Why?
|
Meningeal Neoplasms | 1 | 2022 | 1241 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2013 | 203 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2015 | 602 | 0.110 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2015 | 324 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2017 | 547 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2021 | 2504 | 0.110 |
Why?
|
Drug Synergism | 1 | 2016 | 1794 | 0.110 |
Why?
|
Mouth Neoplasms | 1 | 2017 | 601 | 0.100 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 1115 | 0.100 |
Why?
|
Asbestos | 1 | 2013 | 251 | 0.100 |
Why?
|
Amino Acid Substitution | 2 | 2013 | 1793 | 0.100 |
Why?
|
Carcinogens | 1 | 2013 | 466 | 0.100 |
Why?
|
Urinary Tract | 1 | 2014 | 309 | 0.100 |
Why?
|
Mutant Proteins | 1 | 2013 | 500 | 0.100 |
Why?
|
Genotype | 4 | 2021 | 12952 | 0.100 |
Why?
|
Gene Expression Profiling | 5 | 2020 | 9445 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2015 | 2649 | 0.100 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 3464 | 0.100 |
Why?
|
Abdominal Neoplasms | 1 | 2012 | 292 | 0.090 |
Why?
|
Polyomavirus Infections | 1 | 2012 | 200 | 0.090 |
Why?
|
Paired Box Transcription Factors | 1 | 2011 | 214 | 0.090 |
Why?
|
Genes, Tumor Suppressor | 2 | 2012 | 1097 | 0.090 |
Why?
|
Thoracic Neoplasms | 1 | 2012 | 268 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1897 | 0.090 |
Why?
|
Precancerous Conditions | 2 | 2020 | 975 | 0.090 |
Why?
|
Decerebrate State | 1 | 2009 | 43 | 0.090 |
Why?
|
Tumor Virus Infections | 1 | 2012 | 454 | 0.090 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2014 | 5172 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3595 | 0.090 |
Why?
|
Myelinolysis, Central Pontine | 1 | 2009 | 18 | 0.090 |
Why?
|
Terminology as Topic | 1 | 2016 | 1547 | 0.080 |
Why?
|
Tumor Suppressor Proteins | 2 | 2021 | 2850 | 0.080 |
Why?
|
Osmotic Pressure | 1 | 2009 | 151 | 0.080 |
Why?
|
Cell Proliferation | 2 | 2021 | 10483 | 0.080 |
Why?
|
Epidermal Growth Factor | 1 | 2011 | 709 | 0.080 |
Why?
|
SOXB1 Transcription Factors | 1 | 2010 | 284 | 0.080 |
Why?
|
DNA Copy Number Variations | 2 | 2015 | 1941 | 0.080 |
Why?
|
Prostatic Neoplasms | 2 | 2022 | 11126 | 0.080 |
Why?
|
Pleural Neoplasms | 1 | 2013 | 607 | 0.080 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 303 | 0.080 |
Why?
|
Cisplatin | 1 | 2014 | 1662 | 0.080 |
Why?
|
Child | 9 | 2023 | 77709 | 0.080 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2020 | 2214 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11525 | 0.080 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3646 | 0.080 |
Why?
|
Mesothelioma | 1 | 2013 | 818 | 0.070 |
Why?
|
Gene Dosage | 3 | 2020 | 1252 | 0.070 |
Why?
|
Sirolimus | 1 | 2014 | 1565 | 0.070 |
Why?
|
Boston | 3 | 2016 | 9312 | 0.070 |
Why?
|
Germ-Line Mutation | 2 | 2012 | 1788 | 0.070 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 1038 | 0.070 |
Why?
|
Biopsy | 4 | 2021 | 6755 | 0.070 |
Why?
|
Cell Line, Tumor | 7 | 2021 | 16690 | 0.070 |
Why?
|
Treatment Outcome | 7 | 2020 | 63107 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2013 | 1381 | 0.070 |
Why?
|
Hyponatremia | 1 | 2009 | 298 | 0.070 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2012 | 643 | 0.070 |
Why?
|
Uterine Neoplasms | 1 | 2015 | 1513 | 0.070 |
Why?
|
Endometrial Neoplasms | 1 | 2015 | 1351 | 0.070 |
Why?
|
Biomedical Research | 1 | 2021 | 3309 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39052 | 0.070 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7282 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2013 | 1415 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2022 | 4839 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 17446 | 0.060 |
Why?
|
Risk Assessment | 7 | 2021 | 23336 | 0.060 |
Why?
|
Receptor, erbB-2 | 1 | 2015 | 2417 | 0.060 |
Why?
|
Supratentorial Neoplasms | 1 | 2006 | 160 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 14723 | 0.060 |
Why?
|
Research Design | 1 | 2020 | 5984 | 0.060 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13693 | 0.060 |
Why?
|
Recurrence | 2 | 2013 | 8340 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2703 | 0.060 |
Why?
|
Child, Preschool | 7 | 2021 | 41005 | 0.060 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 9647 | 0.060 |
Why?
|
Risk | 4 | 2019 | 9688 | 0.060 |
Why?
|
Sodium | 1 | 2009 | 1622 | 0.060 |
Why?
|
Radiopharmaceuticals | 2 | 2024 | 2645 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2015 | 2020 | 0.060 |
Why?
|
NF-kappa B | 1 | 2011 | 2499 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3554 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2943 | 0.050 |
Why?
|
Blotting, Western | 3 | 2015 | 5181 | 0.050 |
Why?
|
New South Wales | 1 | 2021 | 66 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2016 | 0.050 |
Why?
|
Prospective Studies | 8 | 2018 | 53290 | 0.050 |
Why?
|
Collagen | 1 | 2010 | 2688 | 0.050 |
Why?
|
Alcoholic Neuropathy | 1 | 2000 | 1 | 0.050 |
Why?
|
Neurofibromin 2 | 1 | 2022 | 267 | 0.050 |
Why?
|
Pedigree | 2 | 2020 | 4642 | 0.050 |
Why?
|
Heart Defects, Congenital | 1 | 2018 | 4583 | 0.050 |
Why?
|
Survival Analysis | 2 | 2015 | 10252 | 0.050 |
Why?
|
Neoadjuvant Therapy | 3 | 2017 | 2727 | 0.050 |
Why?
|
Oncogenes | 2 | 2020 | 1265 | 0.050 |
Why?
|
Risk Factors | 7 | 2021 | 72296 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2917 | 0.050 |
Why?
|
Platinum | 1 | 2022 | 233 | 0.050 |
Why?
|
Racemases and Epimerases | 1 | 2021 | 113 | 0.050 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 315 | 0.050 |
Why?
|
Achievement | 1 | 2021 | 291 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2009 | 2455 | 0.040 |
Why?
|
Cyclin E | 1 | 2020 | 172 | 0.040 |
Why?
|
Keratins | 1 | 2021 | 515 | 0.040 |
Why?
|
Area Under Curve | 1 | 2024 | 1655 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 801 | 0.040 |
Why?
|
New York | 1 | 2021 | 886 | 0.040 |
Why?
|
Tissue Array Analysis | 2 | 2011 | 553 | 0.040 |
Why?
|
Glucose | 2 | 2022 | 4398 | 0.040 |
Why?
|
Animals | 7 | 2021 | 168768 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2022 | 684 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 3480 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2012 | 2736 | 0.040 |
Why?
|
Ganglia, Spinal | 1 | 2000 | 519 | 0.040 |
Why?
|
Cyanosis | 1 | 2018 | 83 | 0.040 |
Why?
|
Zona Fasciculata | 1 | 2017 | 7 | 0.040 |
Why?
|
Zona Reticularis | 1 | 2017 | 8 | 0.040 |
Why?
|
G Protein-Coupled Inwardly-Rectifying Potassium Channels | 1 | 2017 | 64 | 0.040 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2009 | 2737 | 0.040 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2017 | 98 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 705 | 0.040 |
Why?
|
Signal Transduction | 3 | 2021 | 23404 | 0.040 |
Why?
|
Zona Glomerulosa | 1 | 2017 | 86 | 0.040 |
Why?
|
Cadherins | 1 | 2021 | 907 | 0.040 |
Why?
|
Sulfotransferases | 1 | 2017 | 151 | 0.040 |
Why?
|
raf Kinases | 1 | 2016 | 122 | 0.030 |
Why?
|
Adrenal Glands | 1 | 2019 | 546 | 0.030 |
Why?
|
Protein Conformation | 2 | 2014 | 4010 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8642 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2020 | 749 | 0.030 |
Why?
|
beta Catenin | 1 | 2021 | 1059 | 0.030 |
Why?
|
Northern Ireland | 1 | 2015 | 37 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2000 | 1227 | 0.030 |
Why?
|
Calcium Channels, L-Type | 1 | 2017 | 240 | 0.030 |
Why?
|
History, 21st Century | 1 | 2021 | 1534 | 0.030 |
Why?
|
Muscles | 1 | 2020 | 1614 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2016 | 261 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3338 | 0.030 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6234 | 0.030 |
Why?
|
Genome, Human | 1 | 2007 | 4420 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2020 | 1366 | 0.030 |
Why?
|
Prevalence | 3 | 2016 | 15221 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8432 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2014 | 12356 | 0.030 |
Why?
|
Self-Examination | 1 | 2013 | 70 | 0.030 |
Why?
|
History, 20th Century | 1 | 2021 | 2740 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 7798 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2019 | 1758 | 0.030 |
Why?
|
Faculty, Medical | 1 | 2021 | 1181 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2016 | 733 | 0.030 |
Why?
|
Radiography | 2 | 2014 | 7023 | 0.030 |
Why?
|
Hypothyroidism | 1 | 2018 | 658 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2015 | 601 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2006 | 4479 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2012 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2010 | 11486 | 0.030 |
Why?
|
Consensus | 1 | 2021 | 2960 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 1525 | 0.030 |
Why?
|
Antigens, Polyomavirus Transforming | 1 | 2012 | 261 | 0.030 |
Why?
|
Decision Making | 1 | 2006 | 3888 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2019 | 2076 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 2015 | 4554 | 0.030 |
Why?
|
Administration, Oral | 1 | 2019 | 3914 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 2016 | 1180 | 0.020 |
Why?
|
Databases, Factual | 2 | 2017 | 7730 | 0.020 |
Why?
|
Mucous Membrane | 1 | 2014 | 673 | 0.020 |
Why?
|
Intestines | 1 | 2020 | 1924 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2015 | 841 | 0.020 |
Why?
|
Conserved Sequence | 1 | 2014 | 1202 | 0.020 |
Why?
|
Antigens, CD | 1 | 2021 | 4026 | 0.020 |
Why?
|
Glioblastoma | 1 | 2006 | 3481 | 0.020 |
Why?
|
Age Factors | 2 | 2019 | 18373 | 0.020 |
Why?
|
Transcription Factor RelA | 1 | 2011 | 275 | 0.020 |
Why?
|
Western World | 1 | 2009 | 27 | 0.020 |
Why?
|
Survival Rate | 2 | 2017 | 12788 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2949 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3743 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2010 | 299 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2011 | 2916 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2015 | 13035 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1257 | 0.020 |
Why?
|
Incidence | 2 | 2019 | 20952 | 0.020 |
Why?
|
Carcinoma in Situ | 1 | 2014 | 806 | 0.020 |
Why?
|
Mice | 4 | 2021 | 81201 | 0.020 |
Why?
|
Observer Variation | 1 | 2015 | 2593 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2015 | 2373 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8662 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2009 | 295 | 0.020 |
Why?
|
Gene Knockout Techniques | 1 | 2011 | 808 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2013 | 1184 | 0.020 |
Why?
|
Hypoxia, Brain | 1 | 2009 | 133 | 0.020 |
Why?
|
Sex Distribution | 1 | 2013 | 2297 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2019 | 3084 | 0.020 |
Why?
|
United States | 3 | 2021 | 69872 | 0.020 |
Why?
|
Infant | 2 | 2021 | 35134 | 0.020 |
Why?
|
Pons | 1 | 2009 | 245 | 0.020 |
Why?
|
Physical Examination | 1 | 2013 | 1237 | 0.020 |
Why?
|
Sex Factors | 1 | 2021 | 10400 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2020 | 5023 | 0.020 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2007 | 299 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1799 | 0.020 |
Why?
|
Radiotherapy | 1 | 2013 | 1533 | 0.020 |
Why?
|
Logistic Models | 1 | 2021 | 13409 | 0.020 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2006 | 329 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2009 | 20130 | 0.020 |
Why?
|
Vomiting | 1 | 2009 | 637 | 0.020 |
Why?
|
Iatrogenic Disease | 1 | 2009 | 547 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4216 | 0.020 |
Why?
|
Loss of Heterozygosity | 1 | 2007 | 684 | 0.020 |
Why?
|
Myelin Sheath | 1 | 2009 | 652 | 0.020 |
Why?
|
Reoperation | 1 | 2014 | 4201 | 0.020 |
Why?
|
DNA Repair | 1 | 2014 | 2046 | 0.020 |
Why?
|
Brain | 2 | 2009 | 26388 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2014 | 2566 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 6366 | 0.020 |
Why?
|
Genetics, Population | 1 | 2009 | 934 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2009 | 1851 | 0.010 |
Why?
|
Models, Molecular | 1 | 2014 | 5451 | 0.010 |
Why?
|
Thalamus | 1 | 2009 | 1023 | 0.010 |
Why?
|
Chromosome Deletion | 1 | 2007 | 1401 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2009 | 1660 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2012 | 3177 | 0.010 |
Why?
|
Protein Kinase C-epsilon | 1 | 2000 | 43 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13286 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2022 | 8861 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2006 | 1771 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2015 | 13991 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2006 | 3144 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2019 | 25628 | 0.010 |
Why?
|
Physical Stimulation | 1 | 2000 | 525 | 0.010 |
Why?
|
RNA Interference | 1 | 2007 | 2890 | 0.010 |
Why?
|
Neoplasms | 1 | 2007 | 21696 | 0.010 |
Why?
|
Radiation Injuries | 1 | 2006 | 1180 | 0.010 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2000 | 491 | 0.010 |
Why?
|
Nerve Fibers | 1 | 2000 | 687 | 0.010 |
Why?
|
Pain Threshold | 1 | 2000 | 584 | 0.010 |
Why?
|
Aging | 1 | 2015 | 8664 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2011 | 14561 | 0.010 |
Why?
|
Hyperalgesia | 1 | 2000 | 502 | 0.010 |
Why?
|
Seizures | 1 | 2009 | 2859 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2013 | 9274 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2006 | 5524 | 0.010 |
Why?
|
Hot Temperature | 1 | 2000 | 1356 | 0.010 |
Why?
|
Ethanol | 1 | 2000 | 1342 | 0.010 |
Why?
|
Reaction Time | 1 | 2000 | 2098 | 0.010 |
Why?
|
Pregnancy | 1 | 2015 | 29144 | 0.010 |
Why?
|
Action Potentials | 1 | 2000 | 1806 | 0.010 |
Why?
|
Energy Intake | 1 | 2000 | 2148 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2009 | 4257 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2000 | 4933 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2010 | 21748 | 0.010 |
Why?
|
Pain Measurement | 1 | 2000 | 3420 | 0.010 |
Why?
|
Body Weight | 1 | 2000 | 4671 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2000 | 8300 | 0.010 |
Why?
|
Time Factors | 1 | 2010 | 40075 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2007 | 15520 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 2006 | 21833 | 0.000 |
Why?
|
Rats | 1 | 2000 | 24252 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2000 | 18034 | 0.000 |
Why?
|